期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
人血浆中胸腺肽α1的质谱定量方法初探
1
作者 赵芊 王洪允 +1 位作者 胡蓓 江骥 《分析测试学报》 CAS CSCD 北大核心 2004年第z1期15-17,共3页
  胸腺肽α1(Thymosin α1)是一种由28个氨基酸组成的新型免疫调节因子,它可以启动T淋巴细胞的成熟、刺激分泌干扰素及各种淋巴介素,以及增强自然杀伤细胞介导的细胞毒性[1].临床应用范围较为广泛,主要用于治疗恶性肿瘤所致的免疫功...   胸腺肽α1(Thymosin α1)是一种由28个氨基酸组成的新型免疫调节因子,它可以启动T淋巴细胞的成熟、刺激分泌干扰素及各种淋巴介素,以及增强自然杀伤细胞介导的细胞毒性[1].临床应用范围较为广泛,主要用于治疗恶性肿瘤所致的免疫功能低下,乙型、丙型肝炎及其并发症和严重感染或抗生素不能有效控制的感染等,具有广阔的应用前景[2].…… 展开更多
关键词 QSTaR aPI 3000 LC - MS - MS thymosin a 1
下载PDF
The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy 被引量:9
2
作者 Hong-Yuan Lin 《Chinese Journal of Traumatology》 CAS CSCD 2020年第4期190-195,共6页
COVID-19 is known for its magical infectivity,fast transmission and high death toll based on the large number of infected people.From the perspective of the clinical manifestation,autopsy examination and pathophysiolo... COVID-19 is known for its magical infectivity,fast transmission and high death toll based on the large number of infected people.From the perspective of the clinical manifestation,autopsy examination and pathophysiology,the essence of COVID-19 should be viewed as a sepsis induced by viral infection,and has the essential characteristics as sepsis induced by other pathogens.Therefore,in addition to etiological and supportive treatment,immunomodulatory therapy is also appropriate to severe COVID-19.Although there is still a lack of consensus on immunotherapy for sepsis so far,relatively rich experiences have been accumulated in the past decades,which will help us in the treatment of severe COVID-19.This article will elaborate immunotherapy of sepsis,though it may not be consistent. 展开更多
关键词 COVID-19 SEPSIS Immunomodulatory therapy IMMUNOTHERaPY ULINaSTaTIN thymosin a1
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部